Carrier Screening & Counseling - Genetics

1. A woman of Ashkenazi Jewish descent is concerned about her risk of being a carrier for Tay-Sachs disease. The carrier frequency in her population is 1/30. She has a negative enzyme-based carrier screen, which has a detection rate of >98%. Her partner is not of Ashkenazi Jewish descent and has a negative carrier screen. The carrier risk in his population is 1/300. What is the most significant factor in determining the couple's residual risk for an affected child?
   Answer: The high detection rate of the enzyme-based screening. While all factors are relevant, the high detection rate (>98%) of the enzyme-based screen for the woman dramatically reduces her carrier risk from 1/30 to a very small residual risk (approximately 1/1500). The partner's risk is already low (1/300) and is also reduced by his negative screen. Because the woman's initial risk was the highest component of the pre-test risk, the high efficacy of her test provides the most significant reduction and is the most important factor in determining their final (very low) residual risk. The other factors set the baseline but the high detection rate is what drives the final risk to a negligible level.
2. A couple has a child with a severe, autosomal dominant condition known to have a high rate of de novo mutation. Both parents undergo genetic testing and are found not to carry the mutation. They are counseled that their recurrence risk is low but not zero. What is the primary reason for this residual recurrence risk?
   Answer: The possibility of germline mosaicism in one of the parents. When a child has a disorder due to a de novo (new) mutation not found in the parents' somatic cells (e.g., blood), the main reason for a recurrence risk greater than the population risk is germline mosaicism. This is a condition where a subset of a parent's germ cells (sperm or eggs) carries the mutation, while their somatic cells do not. This would not be detected by a standard blood test on the parents. Reduced penetrance (A) would mean a parent has the mutation but no symptoms, which testing would have revealed. Population prevalence (C) and lab error (D) are less likely explanations for the small but acknowledged recurrence risk in this specific scenario.
3. Carrier screening panels have evolved from targeting single diseases to 'expanded carrier screening' (ECS) panels that test for hundreds of conditions simultaneously. A primary ethical challenge raised by ECS that is less prominent in single-disease screening is:
   Answer: the increased likelihood of identifying carriers for conditions with mild or variable phenotypes. When evaluating ethical challenges in genetic screening, you need to distinguish between issues that exist in all forms of screening versus those that are amplified or uniquely created by expanded approaches. Expanded carrier screening (ECS) creates a fundamental ethical dilemma by casting an unprecedentedly wide net. When you test for hundreds of conditions simultaneously, you inevitably identify carriers for diseases with mild symptoms, late onset, or highly variable expression. This creates counseling challenges about conditions that may never significantly impact quality of life, forcing difficult decisions about reproductive choices based on uncertain outcomes. The sheer volume of results in ECS makes encountering these ambiguous findings nearly inevitable, unlike targeted single-disease screening where such scenarios are rare. This makes option A correct. Option B is incorrect because cost issues affect both single-disease and expanded screening - it's not uniquely problematic for ECS. Option C misses the mark because non-paternity discovery is equally likely (or unlikely) whether testing one gene or many, since it depends on inheritance patterns, not panel size. Option D represents a technical challenge present in all genetic testing - imperfect detection rates and residual risk calculations exist whether you're screening for one condition or hundreds. Remember that "expanded" or "comprehensive" screening questions often focus on ethical issues created by information overload and uncertain clinical significance. The key principle is that more testing doesn't always mean better outcomes when it generates results of questionable actionability.
4. A couple undergoes expanded carrier screening. The man is found to be a carrier for autosomal recessive congenital adrenal hyperplasia (CAH). The woman is found to be a carrier for autosomal recessive medium-chain acyl-CoA dehydrogenase deficiency (MCADD). Both have no family history of either condition. Which of the following is the most accurate statement a genetic counselor would provide regarding their reproductive risk?
   Answer: Their children have a 50% chance of being a carrier for CAH and a 50% chance of being a carrier for MCADD, but no risk of being affected by either. For a child to be affected with an autosomal recessive condition, both parents must be carriers for the same condition. In this case, the parents are carriers for two different autosomal recessive disorders. Therefore, they cannot have a child affected with either CAH or MCADD. However, the father has a 50% chance of passing on his CAH allele, and the mother has a 50% chance of passing on her MCADD allele. This makes statement C the most accurate description of their risk.
5. A patient is identified as a carrier for a pathogenic variant in the CFTR gene through routine screening. The patient has two siblings and three first cousins. According to the principles of cascade screening, who should be offered testing next to most efficiently and ethically identify other at-risk family members?
   Answer: The patient's siblings should be tested first, as they each have a 50% chance of being a carrier. Cascade screening is a stepwise process that starts with the closest relatives of the identified individual (the proband). First-degree relatives (siblings, parents, children) are at the highest risk. In this case, the siblings each have a 50% chance of inheriting the same variant and being carriers. Testing them is the most efficient next step. Testing parents (C) can be useful but testing siblings directly addresses the risk in the same generation. Testing all relatives concurrently (A) is inefficient. Prioritizing more distant relatives like cousins (D) over closer ones is illogical and contrary to the cascade screening principle.
6. A couple is planning a pregnancy and is considering their reproductive options. They are both carriers for an autosomal recessive condition that is fatal in early childhood. Which of the following statements accurately distinguishes between the information provided by Chorionic Villus Sampling (CVS) and Preimplantation Genetic Testing (PGT)?
   Answer: PGT is used to test embryos for the condition before a pregnancy is established, while CVS is a diagnostic test performed during an established pregnancy. When you encounter questions about prenatal genetic testing, focus on the timing of each procedure and whether a pregnancy has been established. Understanding the sequence of reproductive events is crucial here. PGT (Preimplantation Genetic Testing) occurs during IVF procedures before any embryo is transferred to the uterus. Embryos are created through fertilization in the laboratory, and a few cells are removed from each embryo for genetic analysis. Only embryos without the recessive condition are selected for transfer, preventing an affected pregnancy from ever being established. This allows the couple to avoid the difficult decision of pregnancy termination. CVS (Chorionic Villus Sampling), on the other hand, is performed between 10-13 weeks of an established pregnancy. A sample of placental tissue (chorionic villi) is obtained and analyzed to determine the fetus's genetic status. Since the pregnancy already exists, if the fetus is affected, the couple faces the decision of whether to continue or terminate. Answer D correctly captures this fundamental distinction: PGT prevents affected pregnancies, while CVS diagnoses them after they're established. Answer A is wrong because CVS involves sampling placental tissue, not maternal blood, and both are diagnostic tests. Answer B reverses the capabilities - both tests can provide complete genetic information about the condition. Answer C incorrectly states both occur after 15 weeks; CVS is performed earlier (10-13 weeks) and PGT occurs before pregnancy entirely. Remember: the key distinguisher is pregnancy establishment - PGT happens before, CVS happens during.
7. A woman of Northern European descent is planning a pregnancy. The carrier frequency for cystic fibrosis (CF) in her population is 1/25. Her partner is from the same population and has no family history of CF. The woman undergoes carrier screening for CF, which has a 90% mutation detection rate. Her test result is negative. What is the approximate risk that their child will have CF?
   Answer: 1/24,100 The correct answer requires a multi-step risk calculation. First, calculate the woman's posterior risk of being a carrier after a negative test using Bayes' theorem. Her prior risk is 1/25. P(Carrier|Negative Test) = [P(Negative|Carrier) P(Carrier)] / [P(Negative|Carrier) P(Carrier) + P(Negative|Not Carrier) P(Not Carrier)]. This is [(0.10 1/25)] / [(0.10 1/25) + (1.0 24/25)] = (0.1/25) / (24.1/25) ≈ 1/241. Her partner's risk remains the population risk, 1/25. The risk for an affected child is P(woman is carrier) × P(man is carrier) × 1/4 = (1/241) × (1/25) × (1/4) = 1/24,100.
8. A healthy couple, who are first cousins, are seeking preconception genetic counseling. They have no known family history of any genetic disorders. The genetic counselor explains that their risk to have a child with an autosomal recessive condition is higher than the general population's risk. What is the quantitative basis for this increased risk?
   Answer: Their child's coefficient of inbreeding is 1/16, representing the probability of inheriting an allele that is identical by descent. When you encounter genetics problems involving consanguineous mating (relatives having children), focus on the coefficient of inbreeding, which quantifies the probability that an individual inherits two copies of the same allele that are identical by descent from a common ancestor. For first cousins, you can calculate this coefficient by tracing inheritance paths. First cousins share one set of grandparents, and there are two possible paths for an allele to travel from a shared grandparent to their child: through each of the cousins' parents. Each step in inheritance has a $\frac{1}{2}$ probability. The path from shared grandparent → cousin 1's parent → cousin 1 → child has probability $(\frac{1}{2})^3$, and the path from the same grandparent → cousin 2's parent → cousin 2 → child also has probability $(\frac{1}{2})^3$. Since there are two shared grandparents, the total coefficient is $2 \times (\frac{1}{2})^3 \times (\frac{1}{2})^3 = 2 \times \frac{1}{64} = \frac{1}{16}$. This represents the increased risk for any autosomal recessive condition. Choice A incorrectly calculates $\frac{1}{8}$ as the probability both cousins inherited the same allele, but this doesn't account for the child's inheritance. Choice B describes individual carrier risk ($\frac{1}{4}$) but doesn't combine this properly for the mating. Choice C incorrectly doubles risk based on two grandparents without proper probability calculations. Remember: For consanguinity problems, always calculate the coefficient of inbreeding using inheritance path probabilities. This directly gives you the quantitative increased risk for recessive conditions.
9. The incidence of spinal muscular atrophy (SMA), an autosomal recessive disorder, is 1/10,000 in a specific population. A man from this population has an affected sister. He and his partner, who has no family history of SMA, are seeking genetic counseling. What is the probability that their first child will be affected with SMA?
   Answer: 1/300 First, calculate the carrier frequency from the incidence using the Hardy-Weinberg principle. Incidence (q²) = 1/10,000, so the allele frequency (q) = 1/100. The carrier frequency (2pq) is approximately 2q = 2(1/100) = 1/50. The man has an affected sister, meaning their parents were both carriers. His risk of being a carrier is 2/3 (genotypes AA, Aa, aA are possible; he is unaffected). His partner's risk is the population risk, 1/50. The final risk for an affected child is P(man is carrier) × P(woman is carrier) × 1/4 = (2/3) × (1/50) × (1/4) = 2/600 = 1/300.
10. The carrier frequency for alpha-thalassemia is high in Southeast Asian populations. Most carrier screening is done by molecular testing. However, in some settings, a complete blood count (CBC) showing microcytosis (low Mean Corpuscular Volume, MCV) is used as a preliminary screen. If a patient of Southeast Asian descent has a normal MCV, how should this result be interpreted in genetic counseling?
    Answer: The patient has a significantly reduced likelihood of being a carrier, but it is not ruled out completely. When you encounter questions about genetic screening tests, remember that most screening methods have limitations in sensitivity and specificity. This question tests your understanding of how to interpret negative screening results in the context of population genetics. Alpha-thalassemia carriers often show microcytosis (low MCV) because reduced alpha-globin production leads to smaller, less hemoglobin-filled red blood cells. However, this relationship isn't absolute. A normal MCV in a Southeast Asian patient significantly reduces the probability they're an alpha-thalassemia carrier, but doesn't eliminate it entirely. Some carriers, particularly those with milder mutations or certain genetic variants, may maintain normal red blood cell indices. This is why molecular testing remains the gold standard for definitive carrier detection. Choice A is wrong because screening tests, especially indirect ones like MCV, cannot provide 100% certainty. There's always some possibility of false negatives. Choice B misses the point entirely—the question asks specifically about alpha-thalassemia carrier status, and a normal MCV doesn't redirect suspicion toward beta-thalassemia. Choice C is incorrect because the normal MCV does provide meaningful information that reduces the patient's likelihood of being a carrier below the baseline population risk. Choice D correctly captures that while the normal MCV is reassuring and significantly lowers the probability of carrier status, it cannot completely rule out the possibility due to the inherent limitations of using MCV as a screening tool. Remember: negative screening results reduce risk but rarely eliminate it completely, especially when using indirect biomarkers rather than direct genetic testing.
11. A 28-year-old man is found to be a carrier for a pathogenic variant associated with Wilson disease. His partner's carrier screen is negative. They are counseled that their risk of having a child with Wilson disease is very low. However, the child will have a 50% chance of being a carrier. The couple is distressed, stating they do not want to 'pass on a genetic problem.' Which of the following is the most appropriate initial response from a genetic counselor adhering to the principle of non-directive counseling?
    Answer: Explore their understanding of what being a 'carrier' means and their specific concerns about passing on the variant. The core of non-directive counseling is to facilitate the patient's own decision-making by ensuring they have a clear understanding of the information and have explored their own values and feelings. The couple's distress indicates a potential misunderstanding or significant anxiety about the meaning of carrier status. The most appropriate initial step is to explore their feelings and the source of their concern (B), rather than immediately reassuring them (A), recommending a specific action (C), or shifting the focus to future testing (D).
12. A carrier screen for a particular disorder has a detection rate of 80%. A woman from a population with a carrier frequency of 1/40 tests negative. Her partner is a known carrier. What is the approximate probability that their child will be affected?
    Answer: 1/784 When you encounter carrier screening questions with imperfect detection rates, you need to update the woman's carrier probability based on her negative test result, then calculate the risk to offspring. Start with the woman's prior carrier probability of $\frac{1}{40}$. Since the test has an 80% detection rate, it misses 20% of carriers. Using Bayes' theorem to find her posterior probability of being a carrier after testing negative: The probability she tests negative if she's a carrier is 0.2 (false negative rate). The probability she tests negative if she's not a carrier is 1.0. Her probability of being a carrier after the negative test is: $\frac{\frac{1}{40} \times 0.2}{\frac{1}{40} \times 0.2 + \frac{39}{40} \times 1.0} = \frac{0.005}{0.005 + 0.975} = \frac{0.005}{0.98} = \frac{1}{196}$ Now for the mating: carrier male (probability = 1) × possibly carrier female (probability = $\frac{1}{196}$). If both are carriers, there's a $\frac{1}{4}$ chance their child will be affected. Risk = $\frac{1}{196} \times 1 \times \frac{1}{4} = \frac{1}{784}$ Answer A ($\frac{1}{784}$) is correct. Answer B ($\frac{1}{200}$) ignores the test result entirely. Answer C ($\frac{1}{160}$) incorrectly applies the detection rate. Answer D ($\frac{1}{6400}$) appears to square the original population frequency incorrectly. Study tip: Always update carrier probabilities when screening tests are involved, especially when detection rates are less than 100%. The key is properly applying Bayes' theorem to incorporate test results.
13. A newborn screening result is positive for biotinidase deficiency. Follow-up testing on the parents reveals that both carry a specific pathogenic allele. However, they also both carry a second common variant in the same gene, known as a 'pseudodeficiency' allele, which reduces enzyme activity in laboratory assays but does not cause clinical symptoms. Which concept does this scenario best illustrate for genetic counselors?
    Answer: The challenge of distinguishing clinically significant alleles from benign variants that can confound screening tests. When you encounter genetic screening scenarios involving enzyme deficiencies, focus on the distinction between laboratory findings and clinical significance. This question tests your understanding of how genetic variants can affect test results without causing disease. The scenario describes a classic example of pseudodeficiency alleles—genetic variants that reduce enzyme activity in laboratory assays but don't cause clinical symptoms. Both parents carry both a true pathogenic allele and a pseudodeficiency allele in the biotinidase gene. This creates a testing challenge because the pseudodeficiency allele can make screening results difficult to interpret, even though it's clinically benign. This perfectly illustrates option A: the challenge of distinguishing clinically significant alleles from benign variants that confound screening tests. Option B (variable expressivity) is incorrect because this involves people with identical genotypes showing different clinical presentations—not the case here, where we're dealing with different types of alleles. Option C (population-specific carrier frequencies) doesn't fit because the scenario isn't about risk assessment calculations or population differences. Option D (mosaicism) is wrong because mosaicism involves having different genetic cell lines within one individual, whereas this scenario involves inherited variants present in all cells. For genetics exams, remember that pseudodeficiency alleles are a recurring theme in newborn screening. Always distinguish between variants that affect laboratory enzyme activity versus those that cause actual clinical disease. This distinction is crucial for genetic counseling and patient management.
14. A woman has a paternal uncle (father's brother) with cystic fibrosis (CF). She has a negative CF carrier screen with a 90% detection rate. What was her prior probability of being a carrier before the test was performed?
    Answer: 1/3 When you encounter genetics problems involving carrier probability, you need to carefully trace inheritance patterns and distinguish between prior probability (before testing) and posterior probability (after testing results). To find this woman's prior carrier probability, trace the inheritance path from her affected uncle. Since cystic fibrosis is autosomal recessive, her uncle has genotype ff. This means both of her paternal grandparents must be carriers (Ff) to have produced an affected child. Her father inherited one allele from each grandparent. Since each grandparent has a 50% chance of passing the f allele, her father has a $\frac{1}{2}$ probability of being a carrier. If her father is a carrier and her mother is from the general population (very low carrier probability), then the woman has a $\frac{1}{2} \times \frac{1}{2} = \frac{1}{4}$ chance of inheriting the f allele from her father. However, we know she's unaffected, so she's either FF or Ff. Using conditional probability: among unaffected individuals with her family history, $\frac{1}{3}$ are carriers and $\frac{2}{3}$ are homozygous normal. Choice A ($\frac{1}{2}$) incorrectly assumes she definitely inherited an allele from a carrier father. Choice B ($\frac{2}{3}$) represents the probability she's not a carrier given she's unaffected. Choice C ($\frac{1}{4}$) is the unconditional probability before considering her unaffected status. Remember: prior probability considers family history but not test results. Always condition on known phenotypes when calculating carrier risks in genetics problems.
15. A woman's brother has Duchenne muscular dystrophy (DMD), an X-linked recessive condition. Their mother is confirmed to be a carrier. The woman undergoes genetic testing for the known familial mutation, and her result is negative. The test has a 98% detection rate. What is the probability that her first son will be affected with DMD?
    Answer: 1/102 The woman's prior probability of being a carrier is 1/2, as her mother is a carrier. A negative test modifies this risk. Using Bayes' theorem, her posterior carrier risk is P(C|neg) = [P(neg|C)P(C)] / [P(neg|C)P(C) + P(neg|~C)P(~C)] = [(0.02)(0.5)] / [(0.02)(0.5) + (1)(0.5)] = 0.01 / 0.51 ≈ 1/51. The risk for her son to be affected is her probability of being a carrier multiplied by the 1/2 chance of passing on the affected X chromosome. Thus, the risk is (1/51) × (1/2) = 1/102.
16. In the context of carrier screening for fragile X syndrome, a premutation carrier female is counseled about two distinct risks: the risk of having a son with fragile X syndrome and her own risk for developing fragile X-associated primary ovarian insufficiency (FXPOI). This counseling scenario is a notable exception to typical autosomal recessive carrier counseling because:
    Answer: the carrier state itself is associated with a direct health risk to the female carrier. Unlike most autosomal recessive conditions where carriers are typically asymptomatic, female carriers of the fragile X premutation are at an increased risk for developing health conditions themselves, such as FXPOI and fragile X-associated tremor/ataxia syndrome (FXTAS). This is a critical counseling point that distinguishes it from conditions like CF or Tay-Sachs, where the counseling focus is almost exclusively on reproductive risk. B is incorrect as females can be affected by the full mutation. C is incorrect as expansion occurs when passed through the mother.

Start this quiz